EUVIMEDEUVIMED entdecken
Crossref

Hemoperfusion Therapy’s Efficiency in Reducing Serum IL-6 Levels and Disease Severity in COVID-19 Patients

Mohammad Bakhshivand, Farid Ghorbaninezhad, Somaye Mirzayi, Nima Hemmat, Khalil Ansarin, Mohammad Reza Ardalan, Ali Taghizadieh, Maseoud Nazemiyeh, Mahdi Jafarlou, Farid Rashidi, Armin Sadeghi, Arsalan Yazdchi und 2 weitere

ImmunoAnalysis · 2022

DOI: 10.34172/ia.2022.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoAnalysis, 2022. Verfasst von Mohammad Bakhshivand und 13 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin (IL)-6, one of the inflammatory mediators involved in severe cases of coronavirus disease-19 (COVID-19), has been implicated in the pathogenesis of this disease. Extracorporeal blood purification has been suggested as one of the therapeutic strategies for COVID-19 patients, due to its favorable effect on the removal of inflammatory cytokines. Here, we investigated the impact of hemoperfusion (HP), a type of extracorporeal blood purification, in serum IL-6 levels and disease severity in COVID-19 patients.

Methods

35 patients with severe COVID-19 were enrolled in this study at the Imam-Reza Hospital, Tabriz University of Medical Sciences, between April 2020 and June 2020. The HA330 disposable HP cartridge was utilized (Jafron Biomedical Company, China). After a hemodialysis catheter was placed, patients underwent HP for at least three days in a row.

Results

Our results indicated that COVID-19 patients’ serum levels of IL-6 significantly diminished following HP (P value≤0.001). Furthermore, a decrease in IL-6 levels following HP demonstrated the effectiveness of this approach (area under the curve [AUC]=0.7102 and P=0.0025).

Conclusion

Taken together, our findings suggest HP as a promising therapeutic option in COVID-19. However, a detailed evaluation of HP’s efficacy is required in large prospective multicenter trials.

Zitieren

APA

Bakhshivand, M., Ghorbaninezhad, F., Mirzayi, S., Hemmat, N., Ansarin, K., Ardalan, M. R., Taghizadieh, A., Nazemiyeh, M., Jafarlou, M., Rashidi, F., Sadeghi, A., Yazdchi, A., Safiri, S., & Mikaeili, H. (2022). Hemoperfusion Therapy’s Efficiency in Reducing Serum IL-6 Levels and Disease Severity in COVID-19 Patients. ImmunoAnalysis. https://doi.org/10.34172/ia.2022.10

Vancouver

Bakhshivand M, Ghorbaninezhad F, Mirzayi S, Hemmat N, Ansarin K, Ardalan MR, et al. Hemoperfusion Therapy’s Efficiency in Reducing Serum IL-6 Levels and Disease Severity in COVID-19 Patients. ImmunoAnalysis. 2022. doi:10.34172/ia.2022.10

BibTeX
@article{Bakhshivand2022,
  author = {Bakhshivand, Mohammad and Ghorbaninezhad, Farid and Mirzayi, Somaye and Hemmat, Nima and Ansarin, Khalil and Ardalan, Mohammad Reza and Taghizadieh, Ali and Nazemiyeh, Maseoud and Jafarlou, Mahdi and Rashidi, Farid and Sadeghi, Armin and Yazdchi, Arsalan and Safiri, Saeid and Mikaeili, Haleh},
  title = {Hemoperfusion Therapy’s Efficiency in Reducing Serum IL-6 Levels and Disease Severity in COVID-19 Patients},
  journal = {ImmunoAnalysis},
  year = {2022},
  doi = {10.34172/ia.2022.10}
}
Kostenlos starten →